# Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis

> **NCT06015113** · NA · NOT_YET_RECRUITING · sponsor: **Xi'an International Medical Center Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Disitamab Vedotin plus pyrotinib or naratinib

## Key facts

- **NCT ID:** NCT06015113
- **Lead sponsor:** Xi'an International Medical Center Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09
- **Primary completion:** 2026-04
- **Final completion:** 2027-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015113, "Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06015113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*